nt and alliance management, Dr. Kramer directed program management activities at KaloBios for three development-stage antibodies, and led the global program management for the XOMA-Servier development candidate gevokizumab. Prior to joining XOMA, Dr. Kramer served as
nt and alliance management, Dr. Kramer directed program management activities at KaloBios for three development-stage antibodies, and led the global program management for the XOMA-Servier development candidate gevokizumab. Prior to joining XOMA, Dr. Kramer served as